Company profile
Acura Pharmaceuticals, Inc.
OTC: ACUR · Healthcare · Drug Manufacturers - Specialty & Generic
#824 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 46
v0.1 · 5/100 weight · pillars only
↑ listing tenure, 3-yr revenue growth · ↓ Altman-Z, return on equity
Methodology →Revenue TTM
$1.6M
Rev growth YoY (TTM)
-56.2%
Net income (FY)
-$879.0k
Employees
9
as of 2026-08-28
Market cap
$6.6k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.6M$1.6M2021
Net income-$879.0k-$879.0k2021
Operating income-$1.2M-$1.2M2021
Total assets$860.0k$860.0k2021
Liabilities$682.0k$682.0k2021
Equity$178.0k$178.0k2021
Revenue trend
FY2017 – FY2021 · USD
FY17
FY18
FY18
FY18
FY18
FY19
FY20
FY21
Revenue by segment
Filed disclosures · FY2016
By product
Nexafed products100%
By geography
Not disclosed.
The read
What is Acura Pharmaceuticals, Inc.’s revenue?
Acura Pharmaceuticals, Inc. booked $1.6M in FY2021 revenue, contracting 56% year over year — slower than 83% of Healthcare companies we track, at a -56.2% net margin.
Peers · Healthcare
James E. Wagner Cultivation Corporation——Cannabis Global Inc.——BG Medicine, Inc.——Celldex Therapeutics, Inc.58COrthometrix, Inc.——Molecule Holdings Inc.——Neighbors
Cook →Key facts
CEORobert Jones
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersPalatine, IL
ExchangeOTC: ACUR
Employees9
IPO date1986-03-28
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.